Company Performance: Tourmaline Bio's financial health, including revenue, profit margins, and clinical trial results, directly impacts investor confidence and stock price.

Market Sentiment: Overall investor mood towards the biotechnology sector and small-cap stocks influences demand and price.

Competition: Success or failure of competitor drugs in the same therapeutic area (like inflammatory bowel disease) can shift market share expectations.

Regulatory Approval: FDA decisions on Tourmaline Bio's drug candidates are major catalysts, as approval significantly increases the company's value.

Economic Conditions: Macroeconomic factors, such as interest rates and inflation, can affect investor risk appetite and capital flows into biotech stocks.

Partnerships & Acquisitions: News of potential collaborations or acquisitions can boost the stock price, reflecting increased potential for growth.

Clinical Trial Data: Positive or negative results from clinical trials are crucial for investor perception of the drug's efficacy and safety.

Management Team: The experience and reputation of Tourmaline Bio's management team can influence investor confidence.

News and Media Coverage: Media reports and analyst ratings can sway investor sentiment and affect trading volume.

Stock Dilution: Issuance of new shares (stock dilution) can decrease the value of existing shares, potentially lowering the price.